Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
2350298-92-7
Molecular formula
C6434H9922N1718O2012S46
Molecular weight
145007 g/mol
Drug class
Programmed cell death protein 1 (PD-1)-blocking monoclonal antibodyimmune checkpoint inhibitor
Mechanism of action
Binds PD-1 on T cells and blocks interaction with PD-L1 and PD-L2, relieving PD-1-mediated inhibitory signalling and restoring antitumour T-cell activity.
Indications / reported uses
In combination with gemcitabine and cisplatin or carboplatin for first-line treatment of adults with recurrent or metastatic non-keratinising nasopharyngeal carcinoma.
As monotherapy for adults with metastatic non-keratinising nasopharyngeal carcinoma that has progressed on or after platinum-based chemotherapy and at least one other prior line of therapy, under the US indication.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Penpulimab Environmental Risk Assessment (ERA) (the Penpulimab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.